1. Home
  2. CTNM vs NKLR Comparison

CTNM vs NKLR Comparison

Compare CTNM & NKLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

SELL

Current Price

$9.57

Market Cap

550.7M

Sector

N/A

ML Signal

SELL

Logo Terra Innovatum Global N.V. Ordinary shares

NKLR

Terra Innovatum Global N.V. Ordinary shares

SELL

Current Price

$2.03

Market Cap

464.1M

Sector

Industrials

ML Signal

SELL

Company Overview

Basic Information
Metric
CTNM
NKLR
Founded
2009
2018
Country
United States
Italy
Employees
N/A
N/A
Industry
Metal Fabrications
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
550.7M
464.1M
IPO Year
2024
2025

Fundamental Metrics

Financial Performance
Metric
CTNM
NKLR
Price
$9.57
$2.03
Analyst Decision
Buy
Strong Buy
Analyst Count
8
5
Target Price
★ $21.43
$16.40
AVG Volume (30 Days)
★ 596.9K
284.1K
Earning Date
11-03-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 0.46
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$6.73
$1.93
52 Week High
$17.79
$7.93

Technical Indicators

Market Signals
Indicator
CTNM
NKLR
Relative Strength Index (RSI) 46.25 35.84
Support Level $8.59 $1.95
Resistance Level $13.72 $2.60
Average True Range (ATR) 0.77 0.22
MACD 0.23 0.06
Stochastic Oscillator 42.33 9.21

Price Performance

Historical Comparison
CTNM
NKLR

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

About NKLR Terra Innovatum Global N.V. Ordinary shares

Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost, and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor, SOLO. SOLO is compact yet extremely powerful, with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.

Share on Social Networks: